Robins H I, Neuberg D S, Benson A B, Pandya K J, Tormey D C
University of Wisconsin Clinical Cancer Center, Madison 53792.
Invest New Drugs. 1990 Nov;8(4):397-9. doi: 10.1007/BF00198600.
The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.
东部肿瘤协作组对氯尼达明用于转移性乳腺癌患者进行了一项II期研究。该药物口服给药，最大日剂量为340 mg/m²。42名患者进入研究。观察到1例部分缓解；无危及生命的毒性反应。本研究结果与两项类似的II期试验结果进行了比较。
